Title: Structure-based optimization of click-based histone deacetylase inhibitors.
Journal: European journal of medicinal chemistry 20110801
Title: Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
Journal: Journal of medicinal chemistry 20110714
Title: Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.
Journal: Leukemia research 20110301
Title: Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).
Journal: Journal of medicinal chemistry 20100408
Title: Chemical phylogenetics of histone deacetylases.
Journal: Nature chemical biology 20100301
Title: Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20091001
Title: Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081015
Title: Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Journal: Blood 20081001
Title: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Journal: International journal of oncology 20081001
Title: Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Journal: Molecular cancer therapeutics 20081001
Title: Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Journal: World journal of gastroenterology 20080621
Title: Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Journal: Neuro-oncology 20080601
Title: Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080515
Title: Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Journal: Neoplasia (New York, N.Y.) 20080401
Title: Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
Journal: Bioorganic & medicinal chemistry letters 20080315
Title: Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase.
Journal: Journal of molecular medicine (Berlin, Germany) 20080101
Title: Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Journal: Journal of medicinal chemistry 20071115
Title: The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Journal: Cancer research 20071001
Title: Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Journal: World journal of gastroenterology 20070921
Title: HDAC inhibitors and cardiac safety.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070201
Title: Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Journal: Molecular cancer therapeutics 20070101
Title: Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Journal: Cancer chemotherapy and pharmacology 20061101
Title: Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
Journal: Cancer research 20060901
Title: In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Journal: Cancer research 20060801
Title: The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
Journal: Molecular pharmacology 20060101
Title: Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Journal: Molecular cancer therapeutics 20051101
Title: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Journal: Molecular cancer therapeutics 20050901
Title: Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Journal: Leukemia 20041201
Title: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Journal: Cancer research 20040915
Title: Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040801
Title: In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
Journal: Biochemical pharmacology 20040701
Title: Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Journal: Haematologica 20040401
Title: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Journal: Cancer research 20040115
Title: The discovery of NVP-LAQ824: from concept to clinic.
Journal: Current medicinal chemistry 20031101
Title: N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Journal: Journal of medicinal chemistry 20031009
Title: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Journal: Blood 20031001
Title: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Journal: Molecular cancer therapeutics 20031001
Title: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Journal: Cancer research 20030815
Title: Atadja P, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004 Jan 15;64(2):689-95.
Title: Cho YS, et al. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). J Med Chem. 2010 Apr 8;53(7):2952-63.
Title: Romanski A, et al. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle. 2012 Sep 1;11(17):3219-26.
